<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xml:lang="EN" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?origin publisher?><?properties no_embargo?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Chemother Pharmacol</journal-id><journal-title>Cancer Chemotherapy and Pharmacology</journal-title><issn pub-type="ppub">0344-5704</issn><issn pub-type="epub">1432-0843</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">886</article-id><article-id pub-id-type="doi">10.1007/s00280-008-0886-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Topoisomerase I and II&#x003b1; protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Tsavaris</surname><given-names>Nicolas</given-names></name><address><phone>+30-210-6463191</phone><fax>+30-210-6463191</fax><email>tsavari1@otenet.gr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lazaris</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kosmas</surname><given-names>Christos</given-names></name><address><email>ckosm1@ath.forthnet.gr</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gouveris</surname><given-names>Panagiotis</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kavantzas</surname><given-names>Nikolaos</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kopterides</surname><given-names>Petros</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Papathomas</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Arapogiannis</surname><given-names>George</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zorzos</surname><given-names>Haralambos</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kyriakou</surname><given-names>Vassiliki</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Patsouris</surname><given-names>Efstathios</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Medical Oncology Unit, Department of Pathophysiology, Medical School, &#x0201c;Laikon&#x0201d; University General Hospital, National and Kapodistrian University of Athens, Athens University School of Medicine, 11527 Athens, Greece </aff><aff id="Aff2"><label>2</label>First Department of Pathology, Medical School, &#x0201c;Laikon&#x0201d; University General Hospital, National and Kapodistrian University of Athens, Athens, Greece </aff><aff id="Aff3"><label>3</label>Second Department of Medical Oncology, &#x0201c;Metaxa&#x0201d; Cancer Hospital, Piraeus, Greece </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>12</month><year>2008</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2009</year></pub-date><volume>64</volume><issue>2</issue><fpage>391</fpage><lpage>398</lpage><history><date date-type="received"><day>2</day><month>9</month><year>2008</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2008</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2008</copyright-statement></permissions><abstract xml:lang="EN"><sec><title>Purpose</title><p>Human DNA topoisomerases I and II (topo-I and -II) are essential for vital cellular processes such as DNA replication, transcription, translation, recombination, and repair. In the present study, we correlate topo-I and -II expression and outcome after chemotherapy in primary and relapsed colorectal cancer.</p></sec><sec><title>Patients and methods</title><p>Patients with colorectal cancer that had recurred, following surgery and adjuvant chemotherapy and underwent a second operation were included in the present study. All had undergone surgical resection of the primary tumor and received post-operatively 5-FU-based (5FU&#x000a0;+&#x000a0;Leucovorin, Mayo Clinic regimen) adjuvant chemotherapy. Tumor tissue was collected at the initial operation from the primary tumor and at the time of recurrence (during the second operation following chemotherapy). All tissue samples were analyzed for levels of expression of both topo-I and topo-IIa using standard three-step immunohistochemistry on paraffin sections.</p></sec><sec><title>Results</title><p>Forty patients were included. Levels of expression of topo-I and topo-II were higher in malignant cells from tumor recurrences compared to primary tumors (<italic>P&#x000a0;</italic>=&#x000a0;0.0001 for both). There was a statistically significant positive relationship between patients age and levels of topo-I (<italic>P&#x000a0;</italic>=&#x000a0;0.011) and topo-II (<italic>P&#x000a0;</italic>=&#x000a0;0.011) expression.</p></sec><sec><title>Conclusions</title><p>The study results reported here underscore the role of topoisomerase expression in colorectal cancer and suggest a potential role in tumor recurrence.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Topoisomerase I</kwd><kwd>Topoisomerase II&#x003b1;</kwd><kwd>Colorectal cancer</kwd><kwd>5-FU</kwd><kwd>Chemotherapy</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2009</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>The aim of the present study was to investigate whether chemotherapy with 5-FU alters the levels of topoisomerase I (topo-I) and II (topo-II) in neoplastic tissues from patients with colorectal cancer. To this end, we examined the relationship between clinical data and the expression of topo I and II in patients treated with 5-FU post-operatively and who underwent surgery at recurrence.</p><p>Human DNA topo-I is an essential nuclear enzyme for vital cellular processes such as DNA replication, transcription, translation, recombination and repair. Topo-I unwinds and uncoils the supercoiled DNA double helix by transiently cleaving one of the two strands and allowing its rotation over the other, following which topo-I reseals the cleaved strand [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. Topo-II works in a similar manner, with the difference that it cleaves both DNA strands, allowing the passage of an intact double helix through the break. The entire reaction takes place at the expense of ATP hydrolysis [<xref ref-type="bibr" rid="CR6">6</xref>]. In contrast to topo-I, which is monomeric, two homologous but distinct isoforms of type II human topoisomerases have been identified, DNA topo-II&#x003b1; and II&#x003b2; [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. The &#x003b1; isoform is the type II topoisomerase that was originally described and characterized in mammalian species [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>Several studies have shown topo-II&#x003b1; to be a reliable marker of cell proliferation in tumors [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. In contrast to topo-II, topo-I levels are not cycle-specific and remain stable throughout the cell cycle [<xref ref-type="bibr" rid="CR10">10</xref>]. Topo-II&#x003b1; plays important roles in DNA synthesis and transcription, as well as chromosomal segregation during mitosis. Beyond its physiological functions, topo-II&#x003b1; is reported to be a sensitive and specific marker of actively proliferating cells (in the late S, G<sub>2</sub> and M-phases of the cell cycle) and has been used as a proliferation marker in studies of colorectal cancer [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. In addition to the well described role of the three MDR-related proteins, topo-II&#x003b1; has been implicated in drug resistance of tumor cells [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>Topo-I catalytic activity has been evaluated in various studies and has been detected in all normal tissues at fairly constant levels [<xref ref-type="bibr" rid="CR10">10</xref>]. Additional parameters were further investigated: topo-I immunoreactive protein levels were estimated by Western blot analysis, and topo-I gene expression (topo-I mRNA) was evaluated by Northern blot analysis. With regard to colorectal tumors, they were found to exhibit 5- to 35-fold increases in topo-I levels compared to the adjacent normal colonic mucosa [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Topo-I expression has also been evaluated by immunohistochemistry in paraffin-embedded human tissues [<xref ref-type="bibr" rid="CR12">12</xref>], and its expression has been demonstrated in numerous neoplastic tissues. Increased topo-I has been shown in ovarian carcinomas (elevated topo-I expression in 43% of tumors) [<xref ref-type="bibr" rid="CR12">12</xref>]; colorectal carcinomas (ranging from 43&#x02013;86% in various studies) [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]; testicular tumors (30&#x02013;38% in seminomas, 30% in embryonal carcinomas, and 100% in teratomas and yolk sac tumors) [<xref ref-type="bibr" rid="CR16">16</xref>]; transitional carcinoma of the bladder (overexpression in 77%) [<xref ref-type="bibr" rid="CR17">17</xref>], and renal cell carcinomas (ranging from 36&#x02013;100% according to grade) [<xref ref-type="bibr" rid="CR18">18</xref>]; malignant melanomas (overexpression in 41.6%) [<xref ref-type="bibr" rid="CR19">19</xref>]; gastric carcinomas (overexpression in 68%) [<xref ref-type="bibr" rid="CR20">20</xref>]; sarcomas (high levels of topo-I in 13%) [<xref ref-type="bibr" rid="CR21">21</xref>]; breast carcinomas (overexpression in 41%) [<xref ref-type="bibr" rid="CR22">22</xref>], oral dysplasias, and squamous cell carcinomas (overexpression in 79 and 92%, respectively) [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR60">24</xref>]. In normal tissues, topo-I expression appeared to be higher in the germinal centers of the tonsil and in the mucosal lymphocytes of the colon, while topo I positivity was also detected in the glandular epithelium of the colon [<xref ref-type="bibr" rid="CR12">12</xref>].</p></sec><sec id="Sec2" sec-type="methods"><title>Patients and methods</title><sec id="Sec3"><title>Patients</title><p>Forty patients with colorectal cancer that had recurred following surgery and adjuvant chemotherapy who underwent a second operation were included in this study. All had undergone surgical resection for their primary tumor and received post-operatively 5-FU-based [5FU and Leucovorin (LV), Mayo Clinic regimen] adjuvant chemotherapy [<xref ref-type="bibr" rid="CR24">25</xref>]. Patients characteristics are described in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Patients characteristics</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">Patients (<italic>n</italic>)</td><td align="left">40</td></tr><tr><td align="left" colspan="2">Gender</td></tr><tr><td align="left">&#x000a0;Men</td><td align="left">25</td></tr><tr><td align="left">&#x000a0;Women</td><td align="left">15</td></tr><tr><td align="left">Median age at diagnosis (years)</td><td align="left">58 (35&#x02013;75)</td></tr><tr><td align="left">Performance status (WHO), 0&#x02013;1</td><td align="left">40</td></tr><tr><td align="left" colspan="2">Location of primary tumor</td></tr><tr><td align="left">&#x000a0;Right colon</td><td align="left">6</td></tr><tr><td align="left">&#x000a0;Left colon</td><td align="left">28</td></tr><tr><td align="left">&#x000a0;Rectum</td><td align="left">6</td></tr><tr><td align="left" colspan="2">Stage (Dukes&#x02019;)</td></tr><tr><td align="left">&#x000a0;B2</td><td align="left">13</td></tr><tr><td align="left">&#x000a0;C</td><td align="left">27</td></tr><tr><td align="left" colspan="2">Relapse</td></tr><tr><td align="left">&#x000a0;Local</td><td align="left">17</td></tr><tr><td align="left">&#x000a0;Distant</td><td align="left">23</td></tr><tr><td align="left" colspan="2">Differentiation</td></tr><tr><td align="left">&#x000a0;Well</td><td align="left">2</td></tr><tr><td align="left">&#x000a0;Moderate</td><td align="left">31</td></tr><tr><td align="left">&#x000a0;Poor</td><td align="left">7</td></tr><tr><td align="left">Disease-free survival (months)</td><td align="left">18 (range, 6&#x02013;79)</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Study plan</title><p>Tumor tissue was collected during the initial operation from the primary tumor, before the administration of any adjuvant chemotherapy and also at the time of recurrence (during the second operation following chemotherapy). All these tissues were analyzed for expression of both topo-I and topo-II&#x003b1;.</p></sec><sec id="Sec5"><title>Determination of topo-I and topo-II&#x003b1;</title><p>The expression of topo-I and topo-II&#x003b1; was studied on paraffin sections by a standard three-step immunohistochemistry. Topogen, an anti-topo-I monoclonal antibody (mAb) (2012-3) was applied. Topogen is a mouse mAb (IgG2b isotype); its epitope has not been mapped [<xref ref-type="bibr" rid="CR25">26</xref>&#x02013;<xref ref-type="bibr" rid="CR27">28</xref>]. The primary mAb JH2.7 for topo-II&#x003b1; (Biocare Medical, CA, USA) is a mouse mAb (IgG<sub>1</sub> isotype) that recognizes a 170-kDa protein, the epitope of which maps between aminoacid 854&#x02013;1447 of topo-II&#x003b1; [<xref ref-type="bibr" rid="CR26">27</xref>&#x02013;<xref ref-type="bibr" rid="CR28">29</xref>]. Counterstaining with hematoxylin was applied in the end of the classical immunohistochemistry procedure.</p></sec><sec id="Sec6"><title>Positive and negative controls</title><p>For the expression of topo-I and &#x02013;IIa, normal human tonsil tissues immunostaining served as positive controls. Non-specific, isotype-matched monoclonal Abs worked well as substitute negative controls [<xref ref-type="bibr" rid="CR25">26</xref>&#x02013;<xref ref-type="bibr" rid="CR28">29</xref>].</p></sec><sec id="Sec7"><title>Determination of topo-I and topo-II&#x003b1; expression</title><p><bold>First step</bold> Sections were examined for quantified immunoreactivity by two independent investigators blinded to any relevant patient clinical data. They evaluated more than 1,000 neoplastic cells in consecutive areas of neoplastic tissue. The numbers of positive cells were then expressed as a percentage of labeled tumor cells with respect to the total number of tumor cells that were evaluated. Immunostaining for topo-I and -II&#x003b1; was graded according to the percentage of tumor cells staining positive (and &#x000b1; for &#x0003c;5%, + for 5&#x02013;50% and ++ for 50 to 75% of cells with positive staining) and intensity of staining (weakly positive, moderately positive, or strongly positive). To simplify the scoring, we graded them as 0 (negative cells), 1 (&#x000b1; and/or &#x0003c;5%), 2 (+ and/or 5&#x02013;50%), 3 (++ and/or 50&#x02013;75%). Then, the sections were evaluated classified in pairs (one section from the first surgery and one section from the second surgery for each patient).</p><p><bold>Second step</bold> The percentages of immunoreactive malignant cells were calculated using an image analysis system with an appropriate software package [Sigma Scan Pro, Version 5.0 (SPSS Science, Erkrath, Germany)]. The ratio was calculated as a percentage of immunohistochemically positive neoplastic cells over the total number (stained and unstained) of neoplastic cells. The membrane, cytoplasmic or nuclear intensity of the specific immunohistochemical stain, was also assessed. All the positively stained cells were classified in two groups (weakly stained and strongly stained).</p><p>DNA ploidy of neoplastic cells was evaluated by image DNA cytometry performed on Feulgen-stained sections. Images were acquired using a Zeiss Axiolab microscope (Carl Zeiss Jena GmbH, Jena, Germany) with a mechanical stage, fitted with a SONY-iris CCD video camera (SONY Corporation, Tokyo, Japan). The latter was connected to a Pentium II personal computer which included the relevant software. Slides were examined at low power magnification (40&#x000d7;) to identify the areas with the highest cellularity. In each case, a total number of &#x02265;200 Feulgen-stained nuclei was selected at high power magnification (400&#x000d7;) and stored as JPEG file [1,550&#x000a0;&#x000d7;&#x000a0;1,070 pixels, 16.7&#x000a0;million colors (24-bit)]. Then the images were converted to gray scale and the staining intensity of the Feulgen-stained nuclei was measured semi-automatically. A classification of the nuclei in pairs according to their staining intensity followed. Finally, the graphic presentation of the nuclei demonstrating their distribution according to their DNA content was also performed.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p>All analyses were performed with SPSS version 10.1 (Statistical Product and Service Solutions; SPSS Inc., Chicago, IL, USA). We used McNemar&#x02019;s paired Chi-square test to assess the possible alteration of the levels of topoisomerases after chemotherapy with 5-FU. Fisher&#x02019;s exact test was performed in order to assess the possible relationship of topoisomerase increase with gender, Dukes&#x02019; stage, tumor grade and localization. Mann&#x02013;Whitney <italic>U</italic> Test was performed to assess a possible relationship between patient age and alteration in topoisomerases levels.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Patients</title><p>Forty patients were included in the present study. Of these, 25 were men and 15 were women. The median age was 58&#x000a0;years (range, 35&#x02013;75). All patients had a performance status (PS) of 0&#x02013;1. Tumor localization at the time of diagnosis was: right colon 6, left colon 28, and rectum 6. According to pathological classification, 13 patients had Dukes B2 tumors, and the remaining 27 Dukes C. With regard to differentiation, 2 tumors were well differentiated, 31 moderately and, 7 were poorly differentiated. Of all these patients, 17 relapsed locally and 23 with distant metastases, with a median relapse-free interval of 18 (range, 6&#x02013;79) months (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). All patients who entered the trial were evaluable for analysis.</p></sec><sec id="Sec11"><title>Ploidy</title><p>Out of 40 primary tumors, 12 were highly aneuploid and the remaining 28 were moderately aneuploid. There was no association between the degree of DNA aneuploidy and the expression of any of the analyzed markers.</p></sec><sec id="Sec12"><title>Topoisomerase I</title><p>Immunohistochemical analysis revealed that levels of topo-I expression were higher in malignant cells from tumor recurrences compared to cells from the primary tumors (<italic>P&#x000a0;</italic>=&#x000a0;0.0001) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>); decreased in grade 1 (<italic>P&#x000a0;</italic>=&#x000a0;0.007) and increased in grade 3 (<italic>P&#x000a0;</italic>=&#x000a0;0.003) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In image analysis evaluation, there was a significant increase in malignant cells from the tumor recurrences (<italic>P</italic>&#x000a0;=&#x000a0;0.0001) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>); low expression was noticed in range 1&#x02013;5 (<italic>P&#x000a0;</italic>=&#x000a0;0.0001) and 26&#x02013;30 (<italic>P&#x000a0;</italic>=&#x000a0;0.0143) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>; Fig. <xref rid="Fig3" ref-type="fig">3</xref>). The increase in topo-I levels was not significantly correlated with gender, performance status (WHO), location of the primary tumor, Dukes&#x02019; stage, grade of differentiation, and localization of relapse. There was a statistically significant relationship between the age of patients and the expression of topo-I (<italic>P&#x000a0;</italic>=&#x000a0;0.011). Patients with an increased expression of topo-I levels were older in age (median&#x000a0;=&#x000a0;62.5) than patients without increased expression (median&#x000a0;=&#x000a0;50).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Photomicroscopic evaluation</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Examined parameters</th><th align="left" colspan="3">Photo, microscopic evaluation</th><th align="left" rowspan="2"><italic>P</italic></th></tr><tr><th align="left">Grade</th><th align="left">First evaluation</th><th align="left">Second evaluation</th></tr></thead><tbody><tr><td align="left" rowspan="4">Topoisomerase I</td><td char="." align="char">0</td><td char="." align="char">7</td><td char="." align="char">0</td><td char="." align="char">0.0117</td></tr><tr><td char="." align="char">1</td><td char="." align="char">13</td><td char="." align="char">1</td><td char="." align="char">0.0007</td></tr><tr><td char="." align="char">2</td><td char="." align="char">17</td><td char="." align="char">26</td><td char="." align="char">0.0722</td></tr><tr><td char="." align="char">3</td><td char="." align="char">3</td><td char="." align="char">13</td><td char="." align="char">0.0103</td></tr><tr><td char="." align="char" colspan="5">Increased: 25, decreased: 0, no change: 15, <italic>P</italic>&#x000a0;=&#x000a0;0.0001</td></tr><tr><td align="left" rowspan="4">Topoisomerase IIa</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td></tr><tr><td char="." align="char">1</td><td char="." align="char">10</td><td char="." align="char">2</td><td char="." align="char">0.0252</td></tr><tr><td char="." align="char">2</td><td char="." align="char">30</td><td char="." align="char">28</td><td char="." align="char">0.8027</td></tr><tr><td char="." align="char">3</td><td char="." align="char">0</td><td char="." align="char">10</td><td char="." align="char">0.0010</td></tr><tr><td char="." align="char" colspan="5">Increased: 18, decreased: 0, no change: 22, <italic>P</italic>&#x000a0;=&#x000a0;0.0001</td></tr></tbody></table></table-wrap><fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Topoisomerase I (Topo-I) expression in relation to tumor grade according to immunohistochemical evaluation</p></caption><graphic position="anchor" xlink:href="280_2008_886_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Image analysis evaluation (%)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Range</th><th align="left">First sample (no.)</th><th align="left">Second sample (no.)</th><th align="left"><italic>P</italic></th><th align="left">Range</th><th align="left">First sample (no.)</th><th align="left">Second sample (no.)</th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left"><italic>Topoisomerase I</italic></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="&#x02013;" align="char">36&#x02013;40</td><td char="." align="char">3</td><td char="." align="char">0</td><td char="." align="char">0.2405</td></tr><tr><td align="left">1&#x02013;5</td><td char="." align="char">21</td><td char="." align="char">1</td><td char="." align="char">0.0001</td><td char="&#x02013;" align="char">41&#x02013;45</td><td char="." align="char">1</td><td char="." align="char">1</td><td char="." align="char">1.000</td></tr><tr><td align="left">6&#x02013;10</td><td char="." align="char">4</td><td char="." align="char">0</td><td char="." align="char">0.1156</td><td char="&#x02013;" align="char">46&#x02013;50</td><td char="." align="char">1</td><td char="." align="char">1</td><td char="." align="char">1.000</td></tr><tr><td align="left">11&#x02013;15</td><td char="." align="char">2</td><td char="." align="char">4</td><td char="." align="char">0.6752</td><td char="&#x02013;" align="char">51&#x02013;55</td><td char="." align="char">2</td><td char="." align="char">4</td><td char="." align="char">0.6752</td></tr><tr><td align="left">16&#x02013;20</td><td char="." align="char">3</td><td char="." align="char">5</td><td char="." align="char">0.7119</td><td char="&#x02013;" align="char">56&#x02013;60</td><td char="." align="char">0</td><td char="." align="char">4</td><td char="." align="char">0.1156</td></tr><tr><td align="left">21&#x02013;25</td><td char="." align="char">2</td><td char="." align="char">3</td><td char="." align="char">1</td><td char="&#x02013;" align="char">61&#x02013;65</td><td char="." align="char">0</td><td char="." align="char">5</td><td char="." align="char">0.0547</td></tr><tr><td align="left">26&#x02013;30</td><td char="." align="char">1</td><td char="." align="char">9</td><td char="." align="char">0.0143</td><td char="&#x02013;" align="char">66&#x02013;70</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left"/></tr><tr><td align="left">31&#x02013;35</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">0.2405</td><td char="&#x02013;" align="char">71&#x02013;80</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left"/></tr><tr><td align="left"><italic>Topoisomerase IIa</italic></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="&#x02013;" align="char">36&#x02013;40</td><td char="." align="char">2</td><td char="." align="char">3</td><td char="." align="char">1</td></tr><tr><td align="left">1&#x02013;5</td><td char="." align="char">10</td><td char="." align="char">4</td><td char="." align="char">0.1395</td><td char="&#x02013;" align="char">41&#x02013;45</td><td char="." align="char">5</td><td char="." align="char">1</td><td char="." align="char">0.2007</td></tr><tr><td align="left">6&#x02013;10</td><td char="." align="char">6</td><td char="." align="char">5</td><td char="." align="char">1</td><td char="&#x02013;" align="char">46&#x02013;50</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">0.2405</td></tr><tr><td align="left">11&#x02013;15</td><td char="." align="char">5</td><td char="." align="char">2</td><td char="." align="char">0.4315</td><td char="&#x02013;" align="char">51&#x02013;55</td><td char="." align="char">0</td><td char="." align="char">2</td><td char="." align="char">0.4937</td></tr><tr><td align="left">16&#x02013;20</td><td char="." align="char">9</td><td char="." align="char">1</td><td char="." align="char">0.0143</td><td char="&#x02013;" align="char">56&#x02013;60</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td></tr><tr><td align="left">21&#x02013;25</td><td char="." align="char">0</td><td char="." align="char">5</td><td char="." align="char">0.0547</td><td char="&#x02013;" align="char">61&#x02013;65</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="." align="char">1</td></tr><tr><td align="left">26&#x02013;30</td><td char="." align="char">3</td><td char="." align="char">3</td><td char="." align="char">1</td><td char="&#x02013;" align="char">66&#x02013;70</td><td char="." align="char">0</td><td char="." align="char">2</td><td char="." align="char">0.4937</td></tr><tr><td align="left">31&#x02013;35</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">0.2405</td><td char="&#x02013;" align="char">71&#x02013;80</td><td char="." align="char">0</td><td char="." align="char">5</td><td char="." align="char">0.0547</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Total</th><th align="left" colspan="3">First determination</th><th align="left" colspan="3">Second determination</th><th align="left" rowspan="2"><italic>P</italic></th></tr><tr><th align="left">Mean</th><th align="left">Median</th><th align="left">Range</th><th align="left">Mean</th><th align="left">Median</th><th align="left">Range</th></tr></thead><tbody><tr><td align="left">Topoisomerase I</td><td align="left">13.875</td><td char="." align="char">4.5</td><td align="left">1&#x02013;54</td><td align="left">35.375</td><td char="." align="char">29.5</td><td align="left">4&#x02013;65</td><td align="left">0.0001</td></tr><tr><td align="left">Topoisomerase IIa</td><td align="left">16.775</td><td char="." align="char">15</td><td align="left">1&#x02013;45</td><td align="left">34.575</td><td char="." align="char">31</td><td align="left">2&#x02013;79</td><td align="left">0.0001</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec13"><title>Topoisomerase II&#x003b1;</title><p>Malignant cells from tumor recurrences showed statistically significantly increased levels of topo-II, compared to those of the primary tumors (<italic>P&#x000a0;</italic>=&#x000a0;0.0001) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>); while topo-II levels were decreased in grade 3 lesions (<italic>P&#x000a0;</italic>=&#x000a0;0.0001) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>; Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). In image analysis, there was a significant increase in malignant cells from tumor recurrences (<italic>P&#x000a0;</italic>=&#x000a0;0.0001) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>); low expression was noticed in the range of 16&#x02013;20 (<italic>P&#x000a0;</italic>=&#x000a0;0.0143) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). There was a statistically significant relationship between the age of patients and increased levels of expression of topo-II&#x003b1; (<italic>P&#x000a0;</italic>=&#x000a0;0.011). Levels of topo-II&#x003b1; expression were higher in malignant cells from tumor recurrences compared to cells from primary tumors (<italic>P&#x000a0;</italic>=&#x000a0;0.0001). There was a statistically significant positive correlation between the age of patients and increased levels of expression topo-II&#x003b1; (<italic>P&#x000a0;</italic>=&#x000a0;0.011). The increase in topo-II&#x003b1; levels did not demonstrate any significant correlations with gender, age, PS (WHO), localization of primary tumor, Dukes&#x02019; stage, tumor grade, and location of relapse when compared to topo-II&#x003b1; levels in the primary tumors (<italic>P&#x000a0;</italic>=&#x000a0;0.0001).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Topoisomerase II&#x003b1; (Topo-II&#x003b1;) expression in relation to tumor grade according to immunohistochemical evaluation</p></caption><graphic position="anchor" xlink:href="280_2008_886_Fig2_HTML" id="MO2"/></fig></p></sec></sec><sec id="Sec14" sec-type="discussion"><title>Discussion</title><p>In our study, 33 out of 40 (83%) samples of colorectal cancer stained positive for topoisomerase (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). This finding is in close agreement with the results of Staley et al. [<xref ref-type="bibr" rid="CR14">14</xref>], who reported 86% of positive staining in 29 samples, but in contrast with the results from Boonsong et al. [<xref ref-type="bibr" rid="CR13">13</xref>], who demonstrated a lower percentage of cells expressing topo-I; 51% of the samples, including 24.4% with &#x0003e;50% positive tumor cells [<xref ref-type="bibr" rid="CR13">13</xref>]. Topo-I immunoreactivity was confined to the nucleus in all samples, being consistent with the role of topo-I as a nuclear protein. For topo-II&#x003b1;, 21 out of 40 (52%) samples of colorectal cancer stained positive (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>; Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>), including 10/40 (25%) with weak positive staining (grade 1). This finding was confirmed by Image Analysis (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). These data are consistent with those reported by Burden and Osheroff [<xref ref-type="bibr" rid="CR6">6</xref>].<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Dispersion diagram of topoisomerase I (Topo-&#x00399;) expression as assessed by immunohistochemistry</p></caption><graphic position="anchor" xlink:href="280_2008_886_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Dispersion diagram of topoisomerase I&#x00399;&#x003b1; Topo-II&#x00391; expression as assessed by immunohistochemistry</p></caption><graphic position="anchor" xlink:href="280_2008_886_Fig4_HTML" id="MO4"/></fig></p><p>In this study, we present significantly increased topo-I and topo-I&#x00399;&#x003b1; expression in recurrent colorectal tumors, reinforcing the view that their expression is likely part of the malignant cells phenotype in recurrent colorectal carcinomas. This observation is in agreement with previous studies [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR29">30</xref>], which demonstrated a direct correlation between thymidylate synthase (TS) and topo-I tumor expression and hypothesized, similar to TS [<xref ref-type="bibr" rid="CR31">31</xref>], that high topo-I expression is related to a more aggressive biological phenotype. Of note, increased topo-II&#x003b1; expression characterizes rapidly proliferating cells [<xref ref-type="bibr" rid="CR6">6</xref>] and represents an accepted marker of aggressive tumor behavior [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p>Since the increase of topo-I and -II&#x003b1; expression was demonstrated following 5-FU-based treatment, it is tempting to attribute this change to 5-FU. High levels of topo-I correlate with sensitivity to camptothecins (irinotecan and topotecan) [<xref ref-type="bibr" rid="CR17">17</xref>], whereas high levels of topo-II&#x003b1; correlate with sensitivity to etoposide, a known topo-II&#x003b1;-targeting agent [<xref ref-type="bibr" rid="CR32">32</xref>]. Thus, it is reasonable to consider applying these agents sequentially for the treatment of colorectal cancer; i.e. 5-FU&#x000a0;&#x02192;&#x000a0;irinotecan and 5-FU&#x000a0;&#x02192;&#x000a0;etoposide.</p><p>Irinotecan (CPT-11), a water soluble camptothecin derivative, is a specific potent inhibitor of topo-I [<xref ref-type="bibr" rid="CR33">33</xref>]. In a European phase II study, irinotecan achieved response rates of 19% in chemotherapy-naive patients and 18% in pretreated patients with advanced disease [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p>Drugs that target topo-II, such as etoposide (VP-16), doxorubicin, and mitoxantrone, are among the most effective anticancer drugs in clinical use. Etoposide destroys cells by inhibiting the ability of topo-II to ligate nucleic acids cleaved during the double-stranded DNA passage reaction [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p>Irinotecan yielded response rates of 15&#x02013;25% in 5-FU-refractory patients [<xref ref-type="bibr" rid="CR35">36</xref>&#x02013;<xref ref-type="bibr" rid="CR43">44</xref>], not dissimilar to those observed in first-line treatment of colorectal cancer (18&#x02013;32%) [<xref ref-type="bibr" rid="CR44">45</xref>&#x02013;<xref ref-type="bibr" rid="CR46">47</xref>] and in contrast to the expected decreasing response rate from the application of irinotecan in second-line treatment. Treating patients with irinotecan upon progression to 5-FU/LV seems to be yielding more significant results compared to the opposite sequence, based in our previous experience, where the best results with sequential monotherapies were obtained when 5-FU/LV was followed by irinotecan (5-FU/LV&#x000a0;&#x02192;&#x000a0;CPT11) at disease progression or relapse [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p>With regard to irinotecan efficacy, in vitro data suggest that topo-I expression could be regarded as an important cellular sensitivity determinant [<xref ref-type="bibr" rid="CR16">16</xref>]. In particular, decreased DNA topo-I expression was correlated with camptothecin-resistant cell lines [<xref ref-type="bibr" rid="CR27">27</xref>], while Jansen et al. [<xref ref-type="bibr" rid="CR36">36</xref>] reported a positive correlation between irinotecan sensitivity and topo-I activity.</p><p>Topo-II&#x003b1; is the primary cytotoxic target of some of the most effective chemotherapeutic drugs, such as the epipodophylotoxins, etoposide (VP-16) and teniposide (VM-26) [<xref ref-type="bibr" rid="CR32">32</xref>]. Studies in previously untreated patients with advanced colorectal carcinoma evaluating the combination of etoposide with cisplatin or 5-FU demonstrated minimal activity in metastatic colorectal cancer [<xref ref-type="bibr" rid="CR47">48</xref>&#x02013;<xref ref-type="bibr" rid="CR50">51</xref>]; there have been no clinical data supporting the in vitro synergy observed between these cytotoxic agents [<xref ref-type="bibr" rid="CR51">52</xref>, <xref ref-type="bibr" rid="CR52">53</xref>]. Other studies failed to prove any benefit with the combination of etoposide with 5-FU or cisplatin/carboplatin [<xref ref-type="bibr" rid="CR54">54</xref>]. However, the combination of etoposide with 5-FU&#x000a0;+&#x000a0;LV had demonstrated some activity when administered as second-line treatment after failure of weekly 5-FU&#x000a0;+&#x000a0;LV in patients with metastatic colorectal cancer [<xref ref-type="bibr" rid="CR54">55</xref>, <xref ref-type="bibr" rid="CR55">56</xref>].</p><p>The results reported herein underscore the role of topoisomerase (topo-I and topo-II&#x003b1;) expression in colorectal cancer. It is believed that translational studies of molecular targets for currently applied cytotoxic and biological agents (like bevacizumab and cetuximab) might form the basis of current and future drug combinations, in rationalizing the optimal chemotherapeutic drug schedule and sequence that, will eventually translate in improved tumor eradication and survival prolongation.</p></sec></body><back><ack><p>We thank Dimitris Boulamatsis for the statistical analysis of the manuscript and Madalena Zlovotska for collection of the data. This trial was supported by a grant from ELKE 80546 of the University of Athens School of Medicine.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Fujimori</surname><given-names>A</given-names></name><name><surname>Pommier</surname><given-names>Y</given-names></name></person-group><article-title>Eukaryotic DNA topoisomerases I</article-title><source>Biochim Biophys Acta</source><year>1995</year><volume>1262</volume><fpage>1</fpage><lpage>14</lpage></citation><citation citation-type="display-unstructured">Gupta M, Fujimori A, Pommier Y (1995) Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1262:1&#x02013;14 <pub-id pub-id-type="pmid">7772596</pub-id></citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pommier</surname><given-names>Y</given-names></name><name><surname>Pourquier</surname><given-names>P</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Strumberg</surname><given-names>D</given-names></name></person-group><article-title>Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme</article-title><source>Biochim Biophys Acta</source><year>1998</year><volume>1400</volume><fpage>83</fpage><lpage>105</lpage></citation><citation citation-type="display-unstructured">Pommier Y, Pourquier P, Fan Y, Strumberg D (1998) Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1400:83&#x02013;105 <pub-id pub-id-type="pmid">9748515</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>L</given-names></name><name><surname>Redinbo</surname><given-names>MR</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Hol</surname><given-names>WG</given-names></name><name><surname>Champoux</surname><given-names>JJ</given-names></name></person-group><article-title>A model for the mechanism of human topoisomerase I</article-title><source>Science</source><year>1998</year><volume>279</volume><fpage>1534</fpage><lpage>1541</lpage><pub-id pub-id-type="doi">10.1126/science.279.5356.1534</pub-id></citation><citation citation-type="display-unstructured">Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ (1998) A model for the mechanism of human topoisomerase I. Science 279:1534&#x02013;1541 <pub-id pub-id-type="pmid">9488652</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merino</surname><given-names>A</given-names></name><name><surname>Madden</surname><given-names>KR</given-names></name><name><surname>Lane</surname><given-names>WS</given-names></name><name><surname>Champoux</surname><given-names>JJ</given-names></name><name><surname>Reinberg</surname><given-names>D</given-names></name></person-group><article-title>DNA topoisomerase I is involved in both repression and activation of transcription</article-title><source>Nature</source><year>1993</year><volume>365</volume><fpage>227</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1038/365227a0</pub-id></citation><citation citation-type="display-unstructured">Merino A, Madden KR, Lane WS, Champoux JJ, Reinberg D (1993) DNA topoisomerase I is involved in both repression and activation of transcription. Nature 365:227&#x02013;232 <pub-id pub-id-type="pmid">8396729</pub-id></citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Florell</surname><given-names>SR</given-names></name><name><surname>Martinchick</surname><given-names>JF</given-names></name><name><surname>Holden</surname><given-names>JA</given-names></name></person-group><article-title>Purification of DNA topoisomerase I from the spleen of a patient with non-Hodgkin&#x02019;s lymphoma</article-title><source>Anticancer Res</source><year>1996</year><volume>16</volume><fpage>3467</fpage><lpage>3474</lpage></citation><citation citation-type="display-unstructured">Florell SR, Martinchick JF, Holden JA (1996) Purification of DNA topoisomerase I from the spleen of a patient with non-Hodgkin&#x02019;s lymphoma. Anticancer Res 16:3467&#x02013;3474 <pub-id pub-id-type="pmid">9042208</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burden</surname><given-names>DA</given-names></name><name><surname>Osheroff</surname><given-names>N</given-names></name></person-group><article-title>Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme</article-title><source>Biochim Biophys Acta</source><year>1998</year><volume>1400</volume><fpage>139</fpage><lpage>154</lpage></citation><citation citation-type="display-unstructured">Burden DA, Osheroff N (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1400:139&#x02013;154 <pub-id pub-id-type="pmid">9748545</pub-id></citation></ref><ref id="CR7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kellner</surname><given-names>U</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Kellner</surname><given-names>A</given-names></name><name><surname>Mantke</surname><given-names>R</given-names></name><name><surname>Roessner</surname><given-names>A</given-names></name><name><surname>R&#x000f6;cken</surname><given-names>C</given-names></name></person-group><article-title>Comparative genomic hybridization. Synchronous occurrence of focal nodular hyperplasia and hepatocellular carcinoma in the same liver is not based on common chromosomal aberrations</article-title><source>Am J Clin Pathol</source><year>2003</year><volume>119</volume><fpage>265</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1309/EF69VNDLVPWVE4QV</pub-id></citation><citation citation-type="display-unstructured">Kellner U, Jacobsen A, Kellner A, Mantke R, Roessner A, R&#x000f6;cken C (2003) Comparative genomic hybridization. Synchronous occurrence of focal nodular hyperplasia and hepatocellular carcinoma in the same liver is not based on common chromosomal aberrations. Am J Clin Pathol 119:265&#x02013;271 <pub-id pub-id-type="pmid">12579998</pub-id></citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakopoulou</surname><given-names>L</given-names></name><name><surname>Zervas</surname><given-names>A</given-names></name><name><surname>Lazaris</surname><given-names>AC</given-names></name><name><surname>Constantinides</surname><given-names>C</given-names></name><name><surname>Stravodimos</surname><given-names>C</given-names></name><name><surname>Davaris</surname><given-names>P</given-names></name><name><surname>Dimopoulos</surname><given-names>C</given-names></name></person-group><article-title>Predictive value of topoisomerase II&#x003b1; immunostaining in urothelial bladder carcinoma</article-title><source>J Clin Pathol</source><year>2001</year><volume>54</volume><fpage>309</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1136/jcp.54.4.309</pub-id></citation><citation citation-type="display-unstructured">Nakopoulou L, Zervas A, Lazaris AC, Constantinides C, Stravodimos C, Davaris P, Dimopoulos C (2001) Predictive value of topoisomerase II&#x003b1; immunostaining in urothelial bladder carcinoma. J Clin Pathol 54:309&#x02013;313 <pub-id pub-id-type="pmid">11304849</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibbons</surname><given-names>D</given-names></name><name><surname>Fogt</surname><given-names>F</given-names></name><name><surname>Kasznica</surname><given-names>J</given-names></name><name><surname>Holden</surname><given-names>J</given-names></name><name><surname>Nikulasson</surname><given-names>S</given-names></name></person-group><article-title>Comparison of topoisomerase II alpha and Ki-67 expression in uterine cervical squamous lesions</article-title><source>Mod Pathol</source><year>1997</year><volume>10</volume><fpage>409</fpage><lpage>413</lpage></citation><citation citation-type="display-unstructured">Gibbons D, Fogt F, Kasznica J, Holden J, Nikulasson S (1997) Comparison of topoisomerase II alpha and Ki-67 expression in uterine cervical squamous lesions. Mod Pathol 10:409&#x02013;413 <pub-id pub-id-type="pmid">9160303</pub-id></citation></ref><ref id="CR10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heck</surname><given-names>MM</given-names></name><name><surname>Hittelman</surname><given-names>WN</given-names></name><name><surname>Earnshaw</surname><given-names>WC</given-names></name></person-group><article-title>Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle</article-title><source>Proc Natl Acad Sci USA</source><year>1988</year><volume>85</volume><fpage>1086</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1073/pnas.85.4.1086</pub-id></citation><citation citation-type="display-unstructured">Heck MM, Hittelman WN, Earnshaw WC (1988) Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85:1086&#x02013;1090 <pub-id pub-id-type="pmid">2829215</pub-id></citation></ref><ref id="CR11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bronstein</surname><given-names>IB</given-names></name><name><surname>Vorobyev</surname><given-names>S</given-names></name><name><surname>Timofeev</surname><given-names>A</given-names></name><name><surname>Jolles</surname><given-names>CJ</given-names></name><name><surname>Alder</surname><given-names>SL</given-names></name><name><surname>Holden</surname><given-names>JA</given-names></name></person-group><article-title>Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies</article-title><source>Oncol Res</source><year>1996</year><volume>8</volume><fpage>17</fpage><lpage>25</lpage></citation><citation citation-type="display-unstructured">Bronstein IB, Vorobyev S, Timofeev A, Jolles CJ, Alder SL, Holden JA (1996) Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies. Oncol Res 8:17&#x02013;25 <pub-id pub-id-type="pmid">8704283</pub-id></citation></ref><ref id="CR12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holden</surname><given-names>JA</given-names></name><name><surname>Rahn</surname><given-names>MP</given-names></name><name><surname>Jolles</surname><given-names>CJ</given-names></name><name><surname>Vorobyev</surname><given-names>SV</given-names></name><name><surname>Bronstein</surname><given-names>IB</given-names></name></person-group><article-title>Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinoma</article-title><source>J Clin Pathol</source><year>1997</year><volume>50</volume><fpage>247</fpage><lpage>253</lpage></citation><citation citation-type="display-unstructured">Holden JA, Rahn MP, Jolles CJ, Vorobyev SV, Bronstein IB (1997) Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinoma. J Clin Pathol 50:247&#x02013;253 </citation></ref><ref id="CR13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boonsong</surname><given-names>A</given-names></name><name><surname>Curran</surname><given-names>S</given-names></name><name><surname>McKay</surname><given-names>JA</given-names></name><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Murray</surname><given-names>GI</given-names></name><name><surname>McLeod</surname><given-names>HL</given-names></name></person-group><article-title>Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases</article-title><source>Hum Pathol</source><year>2002</year><volume>33</volume><fpage>1114</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1053/hupa.2002.129202</pub-id></citation><citation citation-type="display-unstructured">Boonsong A, Curran S, McKay JA, Cassidy J, Murray GI, McLeod HL (2002) Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Hum Pathol 33:1114&#x02013;1119 <pub-id pub-id-type="pmid">12454816</pub-id></citation></ref><ref id="CR14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Staley</surname><given-names>BE</given-names></name><name><surname>Samowitz</surname><given-names>WS</given-names></name><name><surname>Bronstein</surname><given-names>IB</given-names></name><name><surname>Holden</surname><given-names>JA</given-names></name></person-group><article-title>Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon</article-title><source>Mod Pathol</source><year>1999</year><volume>12</volume><fpage>356</fpage><lpage>361</lpage></citation><citation citation-type="display-unstructured">Staley BE, Samowitz WS, Bronstein IB, Holden JA (1999) Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon. Mod Pathol 12:356&#x02013;361 <pub-id pub-id-type="pmid">10229499</pub-id></citation></ref><ref id="CR15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paradiso</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Mangia</surname><given-names>A</given-names></name><name><surname>Chiriatti</surname><given-names>A</given-names></name><name><surname>Simone</surname><given-names>G</given-names></name><name><surname>Zito</surname><given-names>A</given-names></name><name><surname>Montemurro</surname><given-names>S</given-names></name><name><surname>Giuliani</surname><given-names>F</given-names></name><name><surname>Maiello</surname><given-names>E</given-names></name><name><surname>Colucci</surname><given-names>G</given-names></name></person-group><article-title>Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients</article-title><source>Int J Cancer</source><year>2004</year><volume>111</volume><fpage>252</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1002/ijc.20208</pub-id></citation><citation citation-type="display-unstructured">Paradiso A, Xu J, Mangia A, Chiriatti A, Simone G, Zito A, Montemurro S, Giuliani F, Maiello E, Colucci G (2004) Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer 111:252&#x02013;258 <pub-id pub-id-type="pmid">15197779</pub-id></citation></ref><ref id="CR16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>LW</given-names></name><name><surname>Perkins</surname><given-names>SL</given-names></name><name><surname>Bronstein</surname><given-names>IB</given-names></name><name><surname>Holden</surname><given-names>JA</given-names></name></person-group><article-title>Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas</article-title><source>Hum Pathol</source><year>2000</year><volume>31</volume><fpage>728</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1053/hupa.2000.8462</pub-id></citation><citation citation-type="display-unstructured">Coleman LW, Perkins SL, Bronstein IB, Holden JA (2000) Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas. Hum Pathol 31:728&#x02013;733 <pub-id pub-id-type="pmid">10872667</pub-id></citation></ref><ref id="CR17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monnin</surname><given-names>KA</given-names></name><name><surname>Bronstein</surname><given-names>IB</given-names></name><name><surname>Gaffney</surname><given-names>DK</given-names></name><name><surname>Holden</surname><given-names>JA</given-names></name></person-group><article-title>Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression</article-title><source>Hum Pathol</source><year>1999</year><volume>4</volume><fpage>384</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1016/S0046-8177(99)90112-0</pub-id></citation><citation citation-type="display-unstructured">Monnin KA, Bronstein IB, Gaffney DK, Holden JA (1999) Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression. Hum Pathol 4:384&#x02013;391 <pub-id pub-id-type="pmid">10208458</pub-id></citation></ref><ref id="CR18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>D</given-names></name><name><surname>Bronstein</surname><given-names>IB</given-names></name><name><surname>Holden</surname><given-names>JA</given-names></name></person-group><article-title>Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival</article-title><source>Hum Pathol</source><year>2000</year><volume>31</volume><fpage>214</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/S0046-8177(00)80222-1</pub-id></citation><citation citation-type="display-unstructured">Gupta D, Bronstein IB, Holden JA (2000) Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival. Hum Pathol 31:214&#x02013;219 <pub-id pub-id-type="pmid">10685636</pub-id></citation></ref><ref id="CR19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perego</surname><given-names>P</given-names></name><name><surname>Capranico</surname><given-names>G</given-names></name><name><surname>Supino</surname><given-names>R</given-names></name><name><surname>Zunino</surname><given-names>F</given-names></name></person-group><article-title>Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types</article-title><source>Anticancer Drugs</source><year>1994</year><volume>5</volume><fpage>645</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1097/00001813-199412000-00006</pub-id></citation><citation citation-type="display-unstructured">Perego P, Capranico G, Supino R, Zunino F (1994) Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anticancer Drugs 5:645&#x02013;649 <pub-id pub-id-type="pmid">7888702</pub-id></citation></ref><ref id="CR20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>LW</given-names></name><name><surname>Bronstein</surname><given-names>IB</given-names></name><name><surname>Holden</surname><given-names>JA</given-names></name></person-group><article-title>Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas</article-title><source>Anticancer Res</source><year>2001</year><volume>21</volume><fpage>1167</fpage><lpage>1172</lpage></citation><citation citation-type="display-unstructured">Coleman LW, Bronstein IB, Holden JA (2001) Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas. Anticancer Res 21:1167&#x02013;1172 <pub-id pub-id-type="pmid">11396158</pub-id></citation></ref><ref id="CR21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>LW</given-names></name><name><surname>Rohr</surname><given-names>LR</given-names></name><name><surname>Bronstein</surname><given-names>IB</given-names></name><name><surname>Holden</surname><given-names>JA</given-names></name></person-group><article-title>Human DNA topoisomerase I: an anticancer drug target present in human sarcomas</article-title><source>Hum Pathol</source><year>2002</year><volume>33</volume><fpage>599</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1053/hupa.2002.124911</pub-id></citation><citation citation-type="display-unstructured">Coleman LW, Rohr LR, Bronstein IB, Holden JA (2002) Human DNA topoisomerase I: an anticancer drug target present in human sarcomas. Hum Pathol 33:599&#x02013;607 <pub-id pub-id-type="pmid">12152158</pub-id></citation></ref><ref id="CR22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>BJ</given-names></name><name><surname>Bronstein</surname><given-names>IB</given-names></name><name><surname>Holden</surname><given-names>JA</given-names></name></person-group><article-title>Elevations of DNA topoisomerase I in invasive carcinoma of the breast</article-title><source>Breast J</source><year>2001</year><volume>7</volume><fpage>176</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1046/j.1524-4741.2001.007003176.x</pub-id></citation><citation citation-type="display-unstructured">Lynch BJ, Bronstein IB, Holden JA (2001) Elevations of DNA topoisomerase I in invasive carcinoma of the breast. Breast J 7:176&#x02013;180 <pub-id pub-id-type="pmid">11469931</pub-id></citation></ref><ref id="CR23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hafian</surname><given-names>H</given-names></name><name><surname>Venteo</surname><given-names>L</given-names></name><name><surname>Sukhanova</surname><given-names>A</given-names></name><name><surname>Nabiev</surname><given-names>I</given-names></name><name><surname>Lefevre</surname><given-names>B</given-names></name><name><surname>Pluot</surname><given-names>M</given-names></name></person-group><article-title>Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas</article-title><source>Hum Pathol</source><year>2004</year><volume>35</volume><fpage>745</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2004.02.004</pub-id></citation><citation citation-type="display-unstructured">Hafian H, Venteo L, Sukhanova A, Nabiev I, Lefevre B, Pluot M (2004) Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas. Hum Pathol 35:745&#x02013;751 <pub-id pub-id-type="pmid">15188142</pub-id></citation></ref><ref id="CR60"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shamaa</surname><given-names>AA</given-names></name><name><surname>Zyada</surname><given-names>MM</given-names></name><name><surname>Wagner</surname><given-names>MM</given-names></name><name><surname>Awad</surname><given-names>SS</given-names></name><name><surname>Osman</surname><given-names>MM</given-names></name><name><surname>Abdel Azeem</surname><given-names>AA</given-names></name></person-group><article-title>The significance of Epstein Barr Virus (EBV) &#x00026; DNA topoisomerase IIu (DNA&#x02013;TopoII) immunoreactivity in normal oral mucosa, oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC)</article-title><source>Diagn Pathol</source><year>2008</year><volume>3</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.1186/1746-1596-3-45</pub-id></citation><citation citation-type="display-unstructured">Shamaa AA, Zyada MM, Wagner MM, Awad SS, Osman MM, Abdel Azeem AA (2008) The significance of Epstein Barr Virus (EBV) &#x00026; DNA topoisomerase IIu (DNA&#x02013;TopoII) immunoreactivity in normal oral mucosa, oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC). Diagn Pathol 3:45 [Epub ahead of print] <pub-id pub-id-type="pmid">19021895</pub-id></citation></ref><ref id="CR24"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heidelberger</surname><given-names>C</given-names></name><name><surname>Chaudhuri</surname><given-names>NK</given-names></name><name><surname>Danneberg</surname><given-names>P</given-names></name><name><surname>Mooren</surname><given-names>D</given-names></name><name><surname>Griesbach</surname><given-names>L</given-names></name><name><surname>Duschinsky</surname><given-names>R</given-names></name><name><surname>Schnitzer</surname><given-names>RJ</given-names></name><name><surname>Pleven</surname><given-names>E</given-names></name><name><surname>Scheiner</surname><given-names>J</given-names></name></person-group><article-title>Fluorinated pyrimidines: a new class of tumor inhibitory compounds</article-title><source>Nature</source><year>1957</year><volume>179</volume><fpage>663</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1038/179663a0</pub-id></citation><citation citation-type="display-unstructured">Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J (1957) Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature 179:663&#x02013;666 <pub-id pub-id-type="pmid">13418758</pub-id></citation></ref><ref id="CR25"><label>26.</label><citation citation-type="other">Libutti SK, Salz LB, Rustgi AK, Tepper JE (2005) Cancer of the colon. In: Devita VT, Hellman S, Rosenberg S (eds) Cancer: principles and practice of oncology, Chap 29, Sect 8. Lippincott Williams and Wilkins, Philadelphia</citation></ref><ref id="CR26"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gouveris</surname><given-names>P</given-names></name><name><surname>Lazaris</surname><given-names>AC</given-names></name><name><surname>Papathomas</surname><given-names>TG</given-names></name><name><surname>Nonni</surname><given-names>A</given-names></name><name><surname>Kyriakou</surname><given-names>V</given-names></name><name><surname>Delladetsima</surname><given-names>J</given-names></name><name><surname>Patsouris</surname><given-names>ES</given-names></name><name><surname>Tsavaris</surname><given-names>N</given-names></name></person-group><article-title>Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy</article-title><source>J Cancer Res Clin Oncol</source><year>2007</year><volume>133</volume><fpage>1011</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1007/s00432-007-0253-6</pub-id></citation><citation citation-type="display-unstructured">Gouveris P, Lazaris AC, Papathomas TG, Nonni A, Kyriakou V, Delladetsima J, Patsouris ES, Tsavaris N (2007) Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy. J Cancer Res Clin Oncol 133:1011&#x02013;1015 <pub-id pub-id-type="pmid">17605046</pub-id></citation></ref><ref id="CR27"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lazaris</surname><given-names>AC</given-names></name><name><surname>Kavantzas</surname><given-names>NG</given-names></name><name><surname>Zorzos</surname><given-names>HS</given-names></name><name><surname>Tsavaris</surname><given-names>NV</given-names></name><name><surname>Davaris</surname><given-names>PS</given-names></name></person-group><article-title>Markers of drug resistance in relapsing colon cancer</article-title><source>J Cancer Res Clin Oncol</source><year>2002</year><volume>128</volume><fpage>114</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1007/s00432-001-0310-5</pub-id></citation><citation citation-type="display-unstructured">Lazaris AC, Kavantzas NG, Zorzos HS, Tsavaris NV, Davaris PS (2002) Markers of drug resistance in relapsing colon cancer. J Cancer Res Clin Oncol 128:114&#x02013;118 <pub-id pub-id-type="pmid">11862483</pub-id></citation></ref><ref id="CR28"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zorzos</surname><given-names>HS</given-names></name><name><surname>Lazaris</surname><given-names>AC</given-names></name><name><surname>Korkolopoulou</surname><given-names>PA</given-names></name><name><surname>Kavantzas</surname><given-names>NG</given-names></name><name><surname>Tseleni-Balafouta</surname><given-names>S</given-names></name><name><surname>Patsouris</surname><given-names>ES</given-names></name><name><surname>Tsavaris</surname><given-names>NV</given-names></name><name><surname>Davaris</surname><given-names>PS</given-names></name></person-group><article-title>Multidrug resistance proteins and topoisomerase II alpha expression in colon cancer: association with metastatic potential</article-title><source>Pathology</source><year>2003</year><volume>35</volume><fpage>315</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1080/0031302031000150524</pub-id></citation><citation citation-type="display-unstructured">Zorzos HS, Lazaris AC, Korkolopoulou PA, Kavantzas NG, Tseleni-Balafouta S, Patsouris ES, Tsavaris NV, Davaris PS (2003) Multidrug resistance proteins and topoisomerase II alpha expression in colon cancer: association with metastatic potential. Pathology 35:315&#x02013;318 <pub-id pub-id-type="pmid">12959767</pub-id></citation></ref><ref id="CR29"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsavaris</surname><given-names>N</given-names></name><name><surname>Kosmas</surname><given-names>C</given-names></name><name><surname>Zorzos</surname><given-names>H</given-names></name><name><surname>Lazaris</surname><given-names>A</given-names></name><name><surname>Vadiaka</surname><given-names>M</given-names></name><name><surname>Dimitrakopoulos</surname><given-names>A</given-names></name><name><surname>Siakantaris</surname><given-names>MP</given-names></name><name><surname>Rokana</surname><given-names>S</given-names></name><name><surname>Papalambros</surname><given-names>E</given-names></name><name><surname>Pangalis</surname><given-names>GA</given-names></name><name><surname>Davaris</surname><given-names>P</given-names></name></person-group><article-title>Breast cancer after curative chemotherapy in non-Hodgkin&#x02019;s lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer</article-title><source>Oncol Rep</source><year>2004</year><volume>11</volume><fpage>899</fpage><lpage>903</lpage></citation><citation citation-type="display-unstructured">Tsavaris N, Kosmas C, Zorzos H, Lazaris A, Vadiaka M, Dimitrakopoulos A, Siakantaris MP, Rokana S, Papalambros E, Pangalis GA, Davaris P (2004) Breast cancer after curative chemotherapy in non-Hodgkin&#x02019;s lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer. Oncol Rep 11:899&#x02013;903 <pub-id pub-id-type="pmid">15010892</pub-id></citation></ref><ref id="CR30"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ichikawa</surname><given-names>W</given-names></name><name><surname>Uetake</surname><given-names>H</given-names></name><name><surname>Nihei</surname><given-names>Z</given-names></name><name><surname>Mastuo</surname><given-names>K</given-names></name><name><surname>Fujita</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name></person-group><article-title>Topoisomerase I (Topo-I) expression correlates to thymidylate synthase (TS) expression in colorectal cancer (CRC)</article-title><source>Proc Am Soc Clin Oncol</source><year>1999</year><volume>18</volume><fpage>946</fpage></citation><citation citation-type="display-unstructured">Ichikawa W, Uetake H, Nihei Z, Mastuo K, Fujita H, Yamada Y (1999) Topoisomerase I (Topo-I) expression correlates to thymidylate synthase (TS) expression in colorectal cancer (CRC). Proc Am Soc Clin Oncol 18:946 (abstract) </citation></ref><ref id="CR31"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leichman</surname><given-names>CG</given-names></name><name><surname>Lenz</surname><given-names>HJ</given-names></name><name><surname>Leichman</surname><given-names>L</given-names></name><name><surname>Danenberg</surname><given-names>K</given-names></name><name><surname>Baranda</surname><given-names>J</given-names></name><name><surname>Groshen</surname><given-names>S</given-names></name><name><surname>Boswell</surname><given-names>W</given-names></name><name><surname>Metzger</surname><given-names>R</given-names></name><name><surname>Tan</surname><given-names>M</given-names></name><name><surname>Danenberg</surname><given-names>PV</given-names></name></person-group><article-title>Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>3223</fpage><lpage>3229</lpage></citation><citation citation-type="display-unstructured">Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223&#x02013;3229 <pub-id pub-id-type="pmid">9336359</pub-id></citation></ref><ref id="CR32"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hande</surname><given-names>KR</given-names></name></person-group><article-title>Clinical applications of anticancer drugs targeted to topoisomerase II</article-title><source>Biochim Biophys Acta</source><year>1998</year><volume>1400</volume><fpage>173</fpage><lpage>184</lpage></citation><citation citation-type="display-unstructured">Hande KR (1998) Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta 1400:173&#x02013;184 <pub-id pub-id-type="pmid">9748560</pub-id></citation></ref><ref id="CR33"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luzzio</surname><given-names>MJ</given-names></name><name><surname>Besterman</surname><given-names>JM</given-names></name><name><surname>Emerson</surname><given-names>DL</given-names></name><name><surname>Evans</surname><given-names>MG</given-names></name><name><surname>Lackey</surname><given-names>K</given-names></name><name><surname>Leitner</surname><given-names>PL</given-names></name><name><surname>McIntyre</surname><given-names>G</given-names></name><name><surname>Morton</surname><given-names>B</given-names></name><name><surname>Myers</surname><given-names>PL</given-names></name><name><surname>Peel</surname><given-names>M</given-names></name><name><surname>Sisco</surname><given-names>JM</given-names></name><name><surname>Sternbach</surname><given-names>DD</given-names></name><etal/></person-group><article-title>Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I</article-title><source>J Med Chem</source><year>1995</year><volume>38</volume><fpage>395</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1021/jm00003a001</pub-id></citation><citation citation-type="display-unstructured">Luzzio MJ, Besterman JM, Emerson DL, Evans MG, Lackey K, Leitner PL, McIntyre G, Morton B, Myers PL, Peel M, Sisco JM, Sternbach DD et al (1995) Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J Med Chem 38:395&#x02013;401 <pub-id pub-id-type="pmid">7853331</pub-id></citation></ref><ref id="CR34"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bleiberg</surname><given-names>H</given-names></name></person-group><article-title>Continuing the fight against advanced colorectal cancer: new and future treatment options</article-title><source>Anticancer Drugs</source><year>1998</year><volume>9</volume><fpage>18</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1097/00001813-199801000-00002</pub-id></citation><citation citation-type="display-unstructured">Bleiberg H (1998) Continuing the fight against advanced colorectal cancer: new and future treatment options. Anticancer Drugs 9:18&#x02013;28 <pub-id pub-id-type="pmid">9491788</pub-id></citation></ref><ref id="CR35"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilstermann</surname><given-names>AM</given-names></name><name><surname>Bender</surname><given-names>RP</given-names></name><name><surname>Godfrey</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Anklin</surname><given-names>C</given-names></name><name><surname>Berkowitz</surname><given-names>DB</given-names></name><name><surname>Osheroff</surname><given-names>N</given-names></name><name><surname>Graves</surname><given-names>DE</given-names></name></person-group><article-title>Topoisomerase II-drug interaction domains: identification of substituents on etoposide that interact with the enzyme</article-title><source>Biochemistry</source><year>2007</year><volume>46</volume><fpage>8217</fpage><lpage>8225</lpage><pub-id pub-id-type="doi">10.1021/bi700272u</pub-id></citation><citation citation-type="display-unstructured">Wilstermann AM, Bender RP, Godfrey M, Choi S, Anklin C, Berkowitz DB, Osheroff N, Graves DE (2007) Topoisomerase II-drug interaction domains: identification of substituents on etoposide that interact with the enzyme. Biochemistry 46:8217&#x02013;8225 <pub-id pub-id-type="pmid">17580961</pub-id></citation></ref><ref id="CR36"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bognel</surname><given-names>C</given-names></name><name><surname>Rekacewicz</surname><given-names>C</given-names></name><name><surname>Mankarios</surname><given-names>H</given-names></name><name><surname>Pignon</surname><given-names>JP</given-names></name><name><surname>Elias</surname><given-names>D</given-names></name><name><surname>Duvillard</surname><given-names>P</given-names></name><name><surname>Prade</surname><given-names>M</given-names></name><name><surname>Ducreux</surname><given-names>M</given-names></name><name><surname>Kac</surname><given-names>J</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Eschw&#x000e8;ge</surname><given-names>F</given-names></name><name><surname>Lasser</surname><given-names>P</given-names></name></person-group><article-title>Prognostic value of neural invasion in rectal carcinoma: a multivariate analysis on 339 patients with curative resection</article-title><source>Eur J Cancer</source><year>1995</year><volume>31A</volume><fpage>894</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1016/0959-8049(95)00077-1</pub-id></citation><citation citation-type="display-unstructured">Bognel C, Rekacewicz C, Mankarios H, Pignon JP, Elias D, Duvillard P, Prade M, Ducreux M, Kac J, Rougier P, Eschw&#x000e8;ge F, Lasser P (1995) Prognostic value of neural invasion in rectal carcinoma: a multivariate analysis on 339 patients with curative resection. Eur J Cancer 31A:894&#x02013;898 <pub-id pub-id-type="pmid">7646917</pub-id></citation></ref><ref id="CR37"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rothenberg</surname><given-names>ML</given-names></name><name><surname>Burris</surname><given-names>HA</given-names></name></person-group><article-title>Irinotecan as second line therapy for patients with 5-FU refractory colorectal cancer</article-title><source>Proc Am Soc Clin Oncol</source><year>1994</year><volume>13</volume><fpage>198</fpage></citation><citation citation-type="display-unstructured">Rothenberg ML, Burris HA III (1994) Irinotecan as second line therapy for patients with 5-FU refractory colorectal cancer. Proc Am Soc Clin Oncol 13:198 (abstr) </citation></ref><ref id="CR38"><label>39.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conti</surname><given-names>JA</given-names></name><name><surname>Saltz</surname><given-names>L</given-names></name></person-group><article-title>Irinotecan is an active agent in untreated patients with metastatic colorectal cancer</article-title><source>Proc Am Soc Clin Oncol</source><year>1994</year><volume>13</volume><fpage>195</fpage></citation><citation citation-type="display-unstructured">Conti JA, Saltz L (1994) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 13:195 (abstr) </citation></ref><ref id="CR39"><label>40.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pitot</surname><given-names>HC</given-names></name><name><surname>O&#x02019;Connell</surname><given-names>MJ</given-names></name></person-group><article-title>A phase II trial of CPT-11 in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group Study</article-title><source>Proc Am Soc Clin Oncol</source><year>1994</year><volume>13</volume><fpage>197</fpage></citation><citation citation-type="display-unstructured">Pitot HC, O&#x02019;Connell MJ (1994) A phase II trial of CPT-11 in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group Study. Proc Am Soc Clin Oncol 13:197 (abstr) </citation></ref><ref id="CR40"><label>41.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>E</given-names></name><name><surname>Lestingi</surname><given-names>TM</given-names></name><name><surname>Mick</surname><given-names>R</given-names></name><name><surname>Ramirez</surname><given-names>J</given-names></name><name><surname>Vokes</surname><given-names>EE</given-names></name><name><surname>Ratain</surname><given-names>MJ</given-names></name></person-group><article-title>Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea</article-title><source>Cancer Res</source><year>1994</year><volume>54</volume><fpage>3723</fpage><lpage>3725</lpage></citation><citation citation-type="display-unstructured">Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723&#x02013;3725 <pub-id pub-id-type="pmid">8033091</pub-id></citation></ref><ref id="CR41"><label>42.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsavaris</surname><given-names>N</given-names></name><name><surname>Kosmas</surname><given-names>C</given-names></name><name><surname>Skopelitis</surname><given-names>H</given-names></name><name><surname>Papadoniou</surname><given-names>N</given-names></name><name><surname>Polyzos</surname><given-names>A</given-names></name><name><surname>Zografos</surname><given-names>G</given-names></name><name><surname>Adoniou</surname><given-names>E</given-names></name><name><surname>Gryniatsos</surname><given-names>J</given-names></name><name><surname>Felekouras</surname><given-names>E</given-names></name><name><surname>Zacharakis</surname><given-names>M</given-names></name><name><surname>Sigala</surname><given-names>F</given-names></name><name><surname>Bacoyiannis</surname><given-names>C</given-names></name><etal/></person-group><article-title>Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study</article-title><source>Chemotherapy</source><year>2007</year><volume>53</volume><fpage>282</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1159/000102583</pub-id></citation><citation citation-type="display-unstructured">Tsavaris N, Kosmas C, Skopelitis H, Papadoniou N, Polyzos A, Zografos G, Adoniou E, Gryniatsos J, Felekouras E, Zacharakis M, Sigala F, Bacoyiannis C et al (2007) Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study. Chemotherapy 53:282&#x02013;291 <pub-id pub-id-type="pmid">17496414</pub-id></citation></ref><ref id="CR42"><label>43.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gennatas</surname><given-names>C</given-names></name><name><surname>Papaxoinis</surname><given-names>G</given-names></name><name><surname>Michalaki</surname><given-names>V</given-names></name><name><surname>Mouratidou</surname><given-names>D</given-names></name><name><surname>Andreadis</surname><given-names>C</given-names></name><name><surname>Tsavaris</surname><given-names>N</given-names></name><name><surname>Pafiti</surname><given-names>A</given-names></name></person-group><article-title>A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma</article-title><source>J Chemother</source><year>2006</year><volume>18</volume><fpage>538</fpage><lpage>544</lpage></citation><citation citation-type="display-unstructured">Gennatas C, Papaxoinis G, Michalaki V, Mouratidou D, Andreadis C, Tsavaris N, Pafiti A (2006) A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma. J Chemother 18:538&#x02013;544 <pub-id pub-id-type="pmid">17127232</pub-id></citation></ref><ref id="CR43"><label>44.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsavaris</surname><given-names>N</given-names></name><name><surname>Ziras</surname><given-names>N</given-names></name><name><surname>Kosmas</surname><given-names>C</given-names></name><name><surname>Giannakakis</surname><given-names>T</given-names></name><name><surname>Gouveris</surname><given-names>P</given-names></name><name><surname>Vadiaka</surname><given-names>M</given-names></name><name><surname>Dimitrakopoulos</surname><given-names>A</given-names></name><name><surname>Karadima</surname><given-names>D</given-names></name><name><surname>Rokana</surname><given-names>S</given-names></name><name><surname>Papalambros</surname><given-names>E</given-names></name><name><surname>Papastratis</surname><given-names>G</given-names></name><name><surname>Margaris</surname><given-names>H</given-names></name><etal/></person-group><article-title>Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study</article-title><source>Cancer Chemother Pharmacol</source><year>2003</year><volume>52</volume><fpage>514</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1007/s00280-003-0659-z</pub-id></citation><citation citation-type="display-unstructured">Tsavaris N, Ziras N, Kosmas C, Giannakakis T, Gouveris P, Vadiaka M, Dimitrakopoulos A, Karadima D, Rokana S, Papalambros E, Papastratis G, Margaris H et al (2003) Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. Cancer Chemother Pharmacol 52:514&#x02013;519 <pub-id pub-id-type="pmid">14504920</pub-id></citation></ref><ref id="CR44"><label>45.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsavaris</surname><given-names>NB</given-names></name><name><surname>Polyzos</surname><given-names>A</given-names></name><name><surname>Gennatas</surname><given-names>K</given-names></name><name><surname>Kosmas</surname><given-names>Ch</given-names></name><name><surname>Vadiaka</surname><given-names>M</given-names></name><name><surname>Dimitrakopoulos</surname><given-names>A</given-names></name><name><surname>Macheras</surname><given-names>A</given-names></name><name><surname>Papastratis</surname><given-names>G</given-names></name><name><surname>Tsipras</surname><given-names>H</given-names></name><name><surname>Margaris</surname><given-names>H</given-names></name><name><surname>Papalambros</surname><given-names>E</given-names></name><name><surname>Giannopoulos</surname><given-names>A</given-names></name><etal/></person-group><article-title>Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination</article-title><source>Chemotherapy</source><year>2002</year><volume>48</volume><fpage>94</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1159/000057669</pub-id></citation><citation citation-type="display-unstructured">Tsavaris NB, Polyzos A, Gennatas K, Kosmas Ch, Vadiaka M, Dimitrakopoulos A, Macheras A, Papastratis G, Tsipras H, Margaris H, Papalambros E, Giannopoulos A et al (2002) Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination. Chemotherapy 48:94&#x02013;99 <pub-id pub-id-type="pmid">12011542</pub-id></citation></ref><ref id="CR45"><label>46.</label><citation citation-type="other">Mitry E, Ducreux M, Rougier P (1998) Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials. Bull Cancer 38-42</citation></ref><ref id="CR46"><label>47.</label><citation citation-type="other">Van Cutsem E, Peeters M (1998) Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials. Bull Cancer 33-7</citation></ref><ref id="CR47"><label>48.</label><citation citation-type="other">Boige V, Raymond E, Armand JP (1998) Irinotecan: various administration schedules, study of drug combinations, phase I experience. Bull Cancer 26-32</citation></ref><ref id="CR48"><label>49.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Planting</surname><given-names>AS</given-names></name><name><surname>Burg</surname><given-names>ME</given-names></name><name><surname>Bent</surname><given-names>MJ</given-names></name><name><surname>Boer-Dennert</surname><given-names>M</given-names></name><name><surname>Stoter</surname><given-names>G</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name></person-group><article-title>Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer</article-title><source>Br J Cancer</source><year>1996</year><volume>73</volume><fpage>1265</fpage><lpage>1267</lpage></citation><citation citation-type="display-unstructured">Planting AS, van der Burg ME, van den Bent MJ, de Boer-Dennert M, Stoter G, Verweij J (1996) Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer. Br J Cancer 73:1265&#x02013;1267 <pub-id pub-id-type="pmid">8630290</pub-id></citation></ref><ref id="CR49"><label>50.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Passalacqua</surname><given-names>R</given-names></name><name><surname>Bisagni</surname><given-names>G</given-names></name><name><surname>Cocconi</surname><given-names>G</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Di Blasio</surname><given-names>B</given-names></name><name><surname>Ceci</surname><given-names>G</given-names></name></person-group><article-title>Cisplatin and etoposide in advanced colorectal carcinoma</article-title><source>Ann Oncol</source><year>1991</year><volume>2</volume><fpage>687</fpage><lpage>688</lpage></citation><citation citation-type="display-unstructured">Passalacqua R, Bisagni G, Cocconi G, Boni C, Di Blasio B, Ceci G (1991) Cisplatin and etoposide in advanced colorectal carcinoma. Ann Oncol 2:687&#x02013;688 <pub-id pub-id-type="pmid">1742225</pub-id></citation></ref><ref id="CR50"><label>51.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Posner</surname><given-names>M</given-names></name><name><surname>Slapak</surname><given-names>CA</given-names></name><name><surname>Browne</surname><given-names>MJ</given-names></name><name><surname>Clark</surname><given-names>JW</given-names></name><name><surname>Curt</surname><given-names>G</given-names></name><name><surname>Weitberg</surname><given-names>A</given-names></name><name><surname>Calabresi</surname><given-names>P</given-names></name><name><surname>Cummings</surname><given-names>FJ</given-names></name><name><surname>Wiemann</surname><given-names>M</given-names></name><name><surname>Urba</surname><given-names>S</given-names></name></person-group><article-title>A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal cancer</article-title><source>Am J Clin Oncol</source><year>1990</year><volume>13</volume><fpage>455</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1097/00000421-199010000-00019</pub-id></citation><citation citation-type="display-unstructured">Posner M, Slapak CA, Browne MJ, Clark JW, Curt G, Weitberg A, Calabresi P, Cummings FJ, Wiemann M, Urba S (1990) A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal cancer. Am J Clin Oncol 13:455&#x02013;458 <pub-id pub-id-type="pmid">2220666</pub-id></citation></ref><ref id="CR51"><label>52.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Colucci</surname><given-names>G</given-names></name><name><surname>Maiello</surname><given-names>E</given-names></name><name><surname>Giuliani</surname><given-names>F</given-names></name><name><surname>Cifarelli</surname><given-names>RA</given-names></name><name><surname>Giotta</surname><given-names>F</given-names></name></person-group><article-title>Carboplatin and etoposide in previously treated colorectal cancer patients</article-title><source>Tumori</source><year>1995</year><volume>81</volume><fpage>36</fpage><lpage>38</lpage></citation><citation citation-type="display-unstructured">Colucci G, Maiello E, Giuliani F, Cifarelli RA, Giotta F (1995) Carboplatin and etoposide in previously treated colorectal cancer patients. Tumori 81:36&#x02013;38 <pub-id pub-id-type="pmid">7754538</pub-id></citation></ref><ref id="CR52"><label>53.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zelkowitz</surname><given-names>RS</given-names></name><name><surname>Posner</surname><given-names>MR</given-names></name><name><surname>Cummings</surname><given-names>F</given-names></name><name><surname>Beitz</surname><given-names>J</given-names></name><name><surname>Weitberg</surname><given-names>AB</given-names></name></person-group><article-title>A phase I/II trial of 5-fluorouracil and etoposide in metastatic colorectal carcinoma</article-title><source>Am J Clin Oncol</source><year>1989</year><volume>12</volume><fpage>492</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1097/00000421-198912000-00006</pub-id></citation><citation citation-type="display-unstructured">Zelkowitz RS, Posner MR, Cummings F, Beitz J, Weitberg AB (1989) A phase I/II trial of 5-fluorouracil and etoposide in metastatic colorectal carcinoma. Am J Clin Oncol 12:492&#x02013;493 </citation></ref><ref id="CR53"><label>54.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inaba</surname><given-names>M</given-names></name><name><surname>Mitsuhashi</surname><given-names>J</given-names></name><name><surname>Kawada</surname><given-names>S</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name></person-group><article-title>Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis</article-title><source>Jpn J Cancer Res</source><year>1994</year><volume>85</volume><fpage>187</fpage><lpage>193</lpage></citation><citation citation-type="display-unstructured">Inaba M, Mitsuhashi J, Kawada S, Nakano H (1994) Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis. Jpn J Cancer Res 85:187&#x02013;193 <pub-id pub-id-type="pmid">8144400</pub-id></citation></ref><ref id="CR54"><label>55.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stuart</surname><given-names>K</given-names></name><name><surname>Posner</surname><given-names>M</given-names></name><name><surname>Campbell</surname><given-names>K</given-names></name><name><surname>Huberman</surname><given-names>M</given-names></name></person-group><article-title>Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma</article-title><source>Am J Clin Oncol</source><year>1995</year><volume>18</volume><fpage>300</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1097/00000421-199508000-00006</pub-id></citation><citation citation-type="display-unstructured">Stuart K, Posner M, Campbell K, Huberman M (1995) Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma. Am J Clin Oncol 18:300&#x02013;302 <pub-id pub-id-type="pmid">7625370</pub-id></citation></ref><ref id="CR55"><label>56.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsavaris</surname><given-names>N</given-names></name><name><surname>Kosmas</surname><given-names>C</given-names></name><name><surname>Gennatas</surname><given-names>K</given-names></name><name><surname>Vadiaka</surname><given-names>M</given-names></name><name><surname>Skopelitis</surname><given-names>E</given-names></name><name><surname>Xila</surname><given-names>V</given-names></name><name><surname>Rokana</surname><given-names>S</given-names></name><name><surname>Margaris</surname><given-names>E</given-names></name><name><surname>Zografos</surname><given-names>G</given-names></name><name><surname>Papastratis</surname><given-names>G</given-names></name><name><surname>Kouraklis</surname><given-names>G</given-names></name></person-group><article-title>Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU&#x000a0;+&#x000a0;LV pre-treated patients with advanced colorectal cancer</article-title><source>J Chemother</source><year>2002</year><volume>14</volume><fpage>406</fpage><lpage>411</lpage></citation><citation citation-type="display-unstructured">Tsavaris N, Kosmas C, Gennatas K, Vadiaka M, Skopelitis E, Xila V, Rokana S, Margaris E, Zografos G, Papastratis G, Kouraklis G (2002) Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU&#x000a0;+&#x000a0;LV pre-treated patients with advanced colorectal cancer. J Chemother 14:406&#x02013;411 <pub-id pub-id-type="pmid">12420860</pub-id></citation></ref><ref id="CR56"><label>57.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsavaris</surname><given-names>N</given-names></name><name><surname>Kosmas</surname><given-names>C</given-names></name><name><surname>Gennatas</surname><given-names>K</given-names></name><name><surname>Vadiaka</surname><given-names>M</given-names></name><name><surname>Paliaros</surname><given-names>P</given-names></name><name><surname>Dimitrakopoulos</surname><given-names>A</given-names></name><name><surname>Diamantis</surname><given-names>T</given-names></name><name><surname>Tsipras</surname><given-names>H</given-names></name><name><surname>Papastratis</surname><given-names>G</given-names></name></person-group><article-title>Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer</article-title><source>Med Sci Monit</source><year>2002</year><volume>8</volume><fpage>65</fpage><lpage>69</lpage></citation><citation citation-type="display-unstructured">Tsavaris N, Kosmas C, Gennatas K, Vadiaka M, Paliaros P, Dimitrakopoulos A, Diamantis T, Tsipras H, Papastratis G (2002) Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer. Med Sci Monit 8:65&#x02013;69 </citation></ref></ref-list><fn-group><fn><p>An erratum to this article can be found at <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00280-009-0988-7">http://dx.doi.org/10.1007/s00280-009-0988-7</ext-link></p></fn></fn-group></back></article> 